Results of a clinical trial with intermittent doses of adriamycin in lung cancer.
D000230:Adenocarcinoma / Q000188:drug therapy; D000505:Alopecia / Q000139:chemically induced; D001773:Blood Cells / Q000187:drug effects; D001812:Blood-Brain Barrier; D001932:Brain Neoplasms / Q000188:drug therapy; D002277:Carcinoma / Q000188:drug therapy; D018288:Carcinoma, Small Cell / Q000188:drug therapy; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D002986:Clinical Trials as Topic; D004317:Doxorubicin / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D009325:Nausea / Q000139:chemically induced; D009362:Neoplasm Metastasis; D012075:Remission, Spontaneous; D014839:Vomiting / Q000139:chemically induced
D004317:Doxorubicin